Image

BCS CME Satellite Symposium | Evaluation Questionnaire

BCS CME Satellite | Evaluation Questionnaire
(1-Not Likely to 5-Very Likely)
I attest that I have completed this educational activity in its entirety. *
Were faculty disclosures made prior to the start of the CME activity? *

Please rate whether the following educational objectives were met.

Review the clinical trial data on treatment pathways and associated new/emerging therapies that improve overall survival for patients with HER2+ metastatic breast cancer *
Discuss strategies for managing/preventing treatment-related adverse events (TRAEs) in patients with HER2+ metastatic breast cancer *
Identify best practices for individualizing treatment plans based on patient factors in HER2+ metastatic breast cancer *

Please rate the projected impact of this activity on your knowledge, competence, performance, and patient outcomes:

This activity increased my knowledge. *
This activity increased my competence. *
This activity increased my performance. *
This activity increased my patient outcomes. *

Do you feel the activity was scientifically sound and free of commercial bias or influence?

Do you feel the activity was scientifically sound and free of commercial bias or influence?

Please identify how you will change your practice as a result of attending this activity.

This activity validated my current practice. No changes will be made. *
Create/revise protocols, policies, and/or procedures *
Change the management and/or treatment of my patients *
Please indicate any barriers you perceive in implementing these changes. *
Will you attempt to address these barriers in order to implement changes in your competence, performance, and/or patients' outcomes? *
The content of this activity matched my current (or potential) scope of practice. *

Please rate the following faculty - Saturday, September 25th:

Treatment Landscape for HER2+ MBC - Shanu Modi, MD

The speaker was knowledgeable and effective; and the presentation was free of bias and scientifically rigorous *

Management of Cardiac Toxicity of Anti-HER 2
Therapies - Chau T. Dang, MD

The speaker was knowledgeable and effective; and the presentation was free of bias and scientifically rigorous *

Managing Lifestyle-Impacting Toxicities - Neil Iyengar, MD of Anti-HER2 Therapy

The speaker was knowledgeable and effective; and the presentation was free of bias and scientifically rigorous *